MedImmune LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: PlaceboBiological: MEDI8968 600 mg IV, 300 mg SC
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 464
- Registration Number
- NCT01448850
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
- Interventions
- Drug: Aromatase Inhibitor
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 188
- Registration Number
- NCT01446159
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus
Phase 2
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Anifrolumab 1000 mgOther: PlaceboBiological: Anifrolumab 300 mg
- First Posted Date
- 2011-09-22
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 626
- Registration Number
- NCT01438489
- Locations
- 🇺🇦
Research Site, Vinnytsia, Ukraine
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Other: Placebo, Q2/4WBiological: Tralokinumab 300 mg, Q2/4WOther: Placebo Q2WBiological: Tralokinumab 300 mg, Q2W
- First Posted Date
- 2011-07-27
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 689
- Registration Number
- NCT01402986
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2016-09-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 44
- Registration Number
- NCT01352884
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
A Study of the Inflammatory Pathways Associated With Chronic Obstructive Pulmonary Disease Exacerbations
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2012-08-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 26
- Registration Number
- NCT01337661
- Locations
- 🇮🇪
Research Site, Dublin, Ireland
A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma
Completed
- Conditions
- Asthma
- Interventions
- Other: No drug will be used
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2012-10-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 97
- Registration Number
- NCT01334853
- Locations
- 🇺🇸
Research site, Rochester, Minnesota, United States
🇨🇦Research Site, Quebec City, Quebec, Canada
A Study to Evaluate the Safety of MEDI2338 in Subjects With Chronic Obstructive Pulmonary Disease
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Biological: MEDI2338Other: Placebo
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2013-10-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 31
- Registration Number
- NCT01322594
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 78
- Registration Number
- NCT01284231
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Phase 2
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Biological: Sifalimumab 600 mgBiological: Sifalimumab 200 mgBiological: Sifalimumab 1,200 mgOther: Placebo
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 834
- Registration Number
- NCT01283139
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath